Novel Therapeutic Targets for Major Depressive Disorder

  title={Novel Therapeutic Targets for Major Depressive Disorder},
  author={Max A. Lazar and Roger S. McIntyre},
  journal={Neurobiology of Depression},
Basic Hypothesis and Therapeutics Targets of Depression: A Review
  • Anil . Kumar
  • Psychology, Biology
    Archives in Neurology & Neuroscience
  • 2021
The monoamine hypothesis is based on attenuation of monoamines such as serotonin (5-HT), norepinephrine (NE) and dopamine (DA) in the brain regions (hippocampus, limbic system and frontal cortex) that can cause depression like symptoms.
Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications
This study aims to review emerging evidence that provide mechanistic insights between different CNS disorders, neuroinflammation and the kynurenine pathway pertinent to CNS disease pathology that have therapeutic implications for the development of selected and efficacious treatment strategies.
C-reactive protein in patients with major depressive disorder in Zagazig university hospitals.
CRP was elevated in patients with MDD and associated with severity of MDD, which supports the previous findings that inflammatory hypothesis has a great role in major depressive disorder pathogenesis.


Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Novel targets for major depressive disorder are discussed to describe their potential mechanisms of action, the available clinical evidence for these targets, the limitations of available evidence as well as future research directions.
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Of these novel targets, the most promising – and the ones for whom the most evidence exists – appear to be the ionotropic glutamate receptors, which will require health professionals to pre-emptively identify potential responders.
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
It is proposed that therapeutics designed to enhance cellular plasticity and resilience and that counter maladaptive stress-responsive systems may have considerable utility for the treatment of bipolar disorder.
The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications
Current knowledge of the neuroprogressive processes that may occur in MDD is reviewed, including structural brain consequences and potential molecular mechanisms including the role of neurotransmitter systems, inflammatory, oxidative and nitrosative stress pathways, neurotrophins and regulation of neurogenesis, cortisol and the hypothalamic–pituitary–adrenal axis modulation.
The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Being negative at the week 12 end point, and with some positive secondary signals, the study provides only limited support for the role of NAC as a novel adjunctive therapy for MDD, although definitive confirmation remains necessary.
Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development
Converting data implicate mitochondrial dysfunction as an important component of the pathophysiology of bipolar disorder and clinical trials of individual MMs as well as combinations are warranted.
Inflamed moods: A review of the interactions between inflammation and mood disorders
The role of glutamate on the action of antidepressants
  • K. Hashimoto
  • Biology, Psychology
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2011